Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935492 | 0.85 | TDP1 (0.46) | TDP1ALDH1A1SMN1; SMN2MAPTCES1 | |
| SCHEMBL6935112 | 0.84 | SMN1; SMN2 (0.43) | TSHRTDP1ALDH1A1HSD17B10SRC | |
| SCHEMBL6934141 | 0.84 | CYP2D6 (0.43) | TSHRTDP1ALDH1A1HSD17B10SRC | |
| SCHEMBL6932532 | 0.83 | HDAC8 (0.44) | SMN1; SMN2CYP2C19RAB9APOLBKMT2A | |
| SCHEMBL27446293 | 0.82 | TSHR (0.50) | TSHRTDP1SRCSMN1; SMN2CYP3A4 | |
| SCHEMBL7457347 | 0.82 | TSHR (0.50) | TSHRTDP1SRCSMN1; SMN2CYP3A4 | |
| SCHEMBL11455069 | 0.80 | SMN1; SMN2 (0.36) | TSHRALDH1A1SRCSMN1; SMN2CYP1A2 | |
| SCHEMBL11455068 | 0.80 | SMN1; SMN2 (0.36) | TSHRALDH1A1SRCSMN1; SMN2CYP1A2 | |
| SCHEMBL6932501 | 0.78 | PKM (0.47) | TDP1ALDH1A1SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL6157370 | 0.77 | GAA (0.57) | TSHRTDP1ALDH1A1SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200393-B1 | OXIME AMIDES AND HYDRAZONE AMIDES HAVING FUNGICIDAL ACTIVITY | MONSANTO TECHNOLOGY LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1200393-A1 | OXIME AMIDES AND HYDRAZONE AMIDES HAVING FUNGICIDAL ACTIVITY | Monsanto Technology LLC (US) | 2002-05-02 | — | — | EP | disclosed |
| US-20020045655-A1 | Oxime amides and hydrazone amides having fungicidal activity | MONSANTO TECHNOLOGY LLC. | 2002-04-18 | — | — | US | disclosed |
| US-6359156-B1 | CONTROLLING DISEASES IN CEREAL PLANTS | MONSANTO TECHNOLOGY LLC | 2002-03-19 | — | — | US | disclosed |
| US-6297271-B1 | CONTROLLING TAKE-ALL DISEASE IN A PLANT | MONSANTO TECHNOLOGY LLC | 2001-10-02 | — | — | US | disclosed |
| WO-2001012590-A1 | OXYME AMIDES AND HYDRAZONE AMIDES HAVING FUNGICIDAL ACTIVITY | MONSANTO TECHNOLOGY LLC (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045655-A1 | Oxime amides and hydrazone amides having fungicidal activity | AADAC, HAAO, OGA | TSHR 2113/4885TDP1 2011/4885ALDH1A1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.